Prognostic Value Of Tumor Infiltrating Lymphocytes Among HER-2+ Breast Cancer Patients Receiving Trastuzumab-Based Adjuvant Therapy

Diah Ari Safitri, A. Ghozali, J. Kurnianda
{"title":"Prognostic Value Of Tumor Infiltrating Lymphocytes Among HER-2+ Breast Cancer Patients Receiving Trastuzumab-Based Adjuvant Therapy","authors":"Diah Ari Safitri, A. Ghozali, J. Kurnianda","doi":"10.52830/inajcc.v1i2.47","DOIUrl":null,"url":null,"abstract":"Background: Tumor Infiltrating Lymphocytes (TILs) have prognostic value on HER2 positive breast cancer (BC). The absence of standardized method for evaluating TILs causes variations in results of previous studies. This study is performed to evaluate the prognostic value of TILs in HER2 positive BC treated with trastuzumab-based adjuvant therapy using standardized method recommended by the International TILs Working Group. \nAim: To analyze the prognostic value of TILs in HER2 positive BC patients receiving trastuzumab-based adjuvant therapy at Dr. Sardjito General Hospital, Yogyakarta and to analyze proportion differences between high TILs (≥30%) and low TILs (<30%). \nMethods: This is a retropective cohort study on HER2 positive, stage 1-3 BC patients who received trastuzumab-based adjuvant therapy. Histopathology slides from 6 hospitals/laboratoriums were analyzed by two pathologists. \nResults: 73 data were available for analysis. TILs stroma <30% was 65,8% and most patients received combination of anthracyclines, taxanes and trastuzumab (67,1%). There was no difference of overall survival between high and low TILs (p log rank: 0,331). \nConclusion: HER2 positive BC with high TILs did not show better overall survival compared to those with low TILs. The proportion of HER2 positive breast cancer with high TILs was lower than those with low TILs.","PeriodicalId":163217,"journal":{"name":"The Indonesian Journal of Cancer Control","volume":"15 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Indonesian Journal of Cancer Control","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52830/inajcc.v1i2.47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Tumor Infiltrating Lymphocytes (TILs) have prognostic value on HER2 positive breast cancer (BC). The absence of standardized method for evaluating TILs causes variations in results of previous studies. This study is performed to evaluate the prognostic value of TILs in HER2 positive BC treated with trastuzumab-based adjuvant therapy using standardized method recommended by the International TILs Working Group. Aim: To analyze the prognostic value of TILs in HER2 positive BC patients receiving trastuzumab-based adjuvant therapy at Dr. Sardjito General Hospital, Yogyakarta and to analyze proportion differences between high TILs (≥30%) and low TILs (<30%). Methods: This is a retropective cohort study on HER2 positive, stage 1-3 BC patients who received trastuzumab-based adjuvant therapy. Histopathology slides from 6 hospitals/laboratoriums were analyzed by two pathologists. Results: 73 data were available for analysis. TILs stroma <30% was 65,8% and most patients received combination of anthracyclines, taxanes and trastuzumab (67,1%). There was no difference of overall survival between high and low TILs (p log rank: 0,331). Conclusion: HER2 positive BC with high TILs did not show better overall survival compared to those with low TILs. The proportion of HER2 positive breast cancer with high TILs was lower than those with low TILs.
HER-2+乳腺癌患者接受曲妥珠单抗辅助治疗时肿瘤浸润淋巴细胞的预后价值
背景:肿瘤浸润淋巴细胞(肿瘤浸润淋巴细胞)对HER2阳性乳腺癌(BC)具有预后价值。由于缺乏评估TILs的标准化方法,导致以往的研究结果存在差异。本研究采用国际TILs工作组推荐的标准化方法,评估以曲妥珠单抗为基础的辅助治疗HER2阳性BC患者TILs的预后价值。目的:分析在日arta Dr. Sardjito总医院接受曲妥珠单抗辅助治疗的HER2阳性BC患者TILs的预后价值,并分析高TILs(≥30%)和低TILs(<30%)的比例差异。方法:这是一项回顾性队列研究,研究对象为HER2阳性,接受曲妥珠单抗辅助治疗的1-3期BC患者。2名病理学家对6家医院/实验室的组织病理切片进行分析。结果:73份资料可供分析。til间质<30%为65.8%,大多数患者接受蒽环类药物、紫杉烷和曲妥珠单抗联合治疗(67.1%)。高和低TILs之间的总生存率没有差异(p log rank: 0,331)。结论:高TILs的HER2阳性BC患者与低TILs患者相比,并没有表现出更好的总生存率。HER2阳性乳腺癌中TILs高的比例低于TILs低的比例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信